Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | US

Overview

Corporate Details

ISIN(s):: US36870W1009
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
MetaVia Inc. A clinical-stage biotech developing novel drugs for cardiometabolic diseases like obesity and MASH.	United States of America	MTVA
Metsera, Inc. Develops potent, long-acting oral & injectable therapies for obesity & metabolic diseases.	United States of America	MTSR
Mezzion Pharma Co., Ltd. Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.	South Korea	140410
MFC Co., Ltd. A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.	South Korea	432980
Milestone Pharmaceuticals Inc. Developing a self-administered nasal spray for at-home treatment of acute cardiac events.	United States of America	MIST
MIMEDX GROUP, INC. Provides placental-based biologics for advanced wound care, surgical, and burn applications.	United States of America	MDXG
Mind Medicine (MindMed) Inc. Developing psychedelic-inspired medicines and novel therapies for brain health disorders.	United States of America	MNMD
Mineralys Therapeutics, Inc. Developing targeted treatments for hypertension & CKD driven by elevated aldosterone.	United States of America	MLYS
MiNK Therapeutics, Inc. Developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases.	United States of America	INKT
MIRA PHARMACEUTICALS, INC. Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.	United States of America	MIRA